Q1 2026 Holdings
Filed 2026-05-15 | 46 holdings | $1.2B | 13F-HR/A | View on SEC ↗ · Holdings Table ↗
Amended (2026-05-20) | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Erasca Inc(ERAS) | Common | 29479A108 | $196.6M | 12,151,480 | 16.3% |
| Praxis Precision Medicines(PRAX) | Common | 74006W207 | $109.2M | 338,895 | 9.1% |
| Terns Pharmaceuticals Inc(TERN) | Common | 880881107 | $70.4M | 1,334,418 | 5.8% |
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $60.8M | 5,094,668 | 5.1% |
| DBV Technologies SA(DBVT) | SPONSORED ADS | 23306J309 | $55.7M | 2,667,569 | 4.6% |
| Compass Therapeutics Inc(CMPX) | Common | 20454B104 | $50.5M | 9,545,466 | 4.2% |
| Tango Therapeutics Inc(TNGX) | Common | 87583X109 | $45.1M | 2,154,780 | 3.7% |
| SAB Biotherapeutics Inc(SABS) | Common | 78397T202 | $43.7M | 11,420,000 | 3.6% |
| Corvus Pharmaceuticals Holdings(CRVS) | Common | 221015100 | $41.0M | 2,805,816 | 3.4% |
| Bright Minds Biosciences Inc(DRUG) | Common | 10919W405 | $40.7M | 557,172 | 3.4% |
| Sinovac Biotech Ltd.(SVA) | SHS | P8696W104 | $38.2M | 5,903,000 | 3.2% |
| Dianthus Therapeutics Inc(DNTH) | Common | 252828108 | $29.7M | 353,998 | 2.5% |
| Dyne Therapeutics Inc(DYN) | Common | 26818M108 | $28.2M | 1,557,466 | 2.3% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $26.7M | 239,539 | 2.2% |
| Minerva Neurosciences Inc(NERV) | Common | 603380205 | $26.0M | 4,322,747 | 2.2% |
| Aclaris Therapeutics, Inc.(ACRS) | Common | 00461U105 | $25.0M | 6,666,666 | 2.1% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $23.4M | 1,848,786 | 1.9% |
| Alto Neuroscience Inc(ANRO) | Common | 02157Q109 | $23.3M | 1,035,551 | 1.9% |
| Sensei Biotherapeutics Inc(SNSE) | Common | 81728A207 | $22.8M | 722,020 | 1.9% |
| Arrivent BioPharma Inc(AVBP) | Common | 04272N102 | $20.4M | 885,916 | 1.7% |
| LB Pharmaceuticals Inc(LBRX) | Common | 50180M108 | $19.7M | 800,000 | 1.6% |
| Veradermics Inc(MANE) | Common | 922967104 | $18.9M | 300,000 | 1.6% |
| Camp4 Therapeutics Inc(CAMP) | Common | 13463J101 | $18.7M | 4,246,568 | 1.6% |
| Moonlake Immunotherapeutics(MLTX) | Common | 61559X104 | $18.6M | 1,000,000 | 1.5% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $17.2M | 1,612,903 | 1.4% |
| Cogent Biosciences Inc(COGT) | Common | 19240Q201 | $16.3M | 422,300 | 1.4% |
| Geron Corp(GERN) | Common | 374163103 | $12.9M | 8,671,797 | 1.1% |
| Unicycive Therapeutics(UNCY) | Common | 90466Y202 | $11.8M | 1,789,916 | 1.0% |
| An2 Therapeutics Inc(ANTX) | Common | 037326105 | $10.8M | 3,153,640 | 0.9% |
| Olema Pharmaceuticals Inc(OLMA) | Common | 68062P106 | $10.0M | 671,843 | 0.8% |
| Soleno Therapeutics Inc(SLNO) | Common | 834203309 | $9.9M | 294,909 | 0.8% |
| Eupraxia Pharmaceuticals Inc(EPRX) | Common | 29842P105 | $9.8M | 1,350,000 | 0.8% |
| Onkure Therapeutics Inc(OKUR) | Common | 68277Q105 | $8.0M | 1,927,710 | 0.7% |
| Surrozen Inc(SRZN) | Common | 86889P208 | $7.6M | 260,000 | 0.6% |
| ALX Oncology Holdings Inc(ALXO) | Common | 00166B105 | $6.4M | 3,184,713 | 0.5% |
| Monopar Therapeutics Inc(MNPR) | Common | 61023L207 | $5.0M | 90,500 | 0.4% |
| Satellos Bioscience Inc(MSLE)A | Common | 80401L803 | $4.6M | 813,666 | 0.4% |
| Pepgen Inc(PEPG) | Common | 713317105 | $4.1M | 2,325,000 | 0.3% |
| Sera Prognostics Inc(SERA) | Common | 81749D107 | $3.4M | 1,650,440 | 0.3% |
| Tenax Therapeutics Inc(TENX) | Common | 88032L605 | $3.3M | 208,333 | 0.3% |
| Viridian Therapeutics Inc(VRDN) | Common | 92790C104 | $3.3M | 166,288 | 0.3% |
| Instil Bio Inc(TIL) | Common | 45783C200 | $2.4M | 292,743 | 0.2% |
| Pasithea Therapeutics Corp(KTTA) | Common | 70261F202 | $1.6M | 2,100,000 | 0.1% |
| Compass Pathway PLC(CMPS) | SPONSORED ADS | 20451W101 | $1.1M | 200,000 | 0.1% |
| Bolt Therapeutics Inc(BOLT) | Common | 097702203 | $292.6K | 72,414 | 0.0% |
| Precision Biosciences Inc(DTIL) | Common | 74019P207 | $25.7K | 4,675 | 0.0% |